Home/Entera Bio/Phillip Schwartz

PS

Phillip Schwartz

Chief Financial Officer

Therapeutic Areas

Endocrinology Metabolic Bone Diseases

Entera Bio Pipeline

Drug	Indication	Phase
EB613	Osteoporosis (postmenopausal women)	Phase 3
EB612	Hypoparathyroidism	Phase 2
EBP05	Osteoporosis	Preclinical

Leadership Team at Entera Bio

Miranda (Tolman) So

Chief Executive Officer and Director

Dr. Arthur Santora

Chief Medical Officer

Dr. William Levine

Chief Scientific Officer

Dr. Roger Garceau

Chief Development Officer

Dr. John P. Bilezikian

Chair of the Scientific Advisory Board

Gerald Lieberman

Chairman of the Board of Directors

Dr. Richard B. Mazess

Dr. James A. Manganello

View full Entera Bio profile